CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 

Genocea Biosciences Inc 's Leverage Ratio

GNCA's quarterly Leverage Ratio and Total Liabilities, Equity growth


In Spite of the repayements of liabilities of -8.61%, in I Quarter 2022 ,Leverage Ratio deteriorated to 2.13, below the Genocea Biosciences Inc 's average Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the first quarter 2022, 163 other companies have achieved lower Leverage Ratio than Genocea Biosciences Inc in the I Quarter 2022. While Leverage Ratio total ranking has deteriorated compared to the forth quarter 2021 from 1521 to 3633 .

Explain Leverage Ratio?
Who are GNCA Customers?
What are GNCA´s Total Liabilities?


GNCA Leverage Ratio (Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Equity Change 602.89 % 201.44 % 87.23 % -49.55 % -86.46 %
Y / Y Total Liabilities Change -67.87 % -67.72 % -68.5 % 125.77 % 155.37 %
Leverage Ratio MRQ 2.13 1.07 0.72 18.08 46.64
GNCA's Total Ranking # 3633 # 1521 # 157 # 289 # 4333
Seq. Equity Change -54.26 % -28.43 % 832.9 % 130.14 % -80.38 %
Seq. Total Liabilities Change -8.61 % 6.66 % -63.06 % -10.77 % -8.19 %



Leverage Ratio first quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 164
Healthcare Sector # 977
Overall Market # 3633


Leverage Ratio Statistics
High Average Low
46.64 3.6 0.14
(Mar 31 2021)   (Sep 30 2015)




Financial Statements
Genocea Biosciences Inc 's Equity $ 12 Millions Visit GNCA's Balance sheet
Genocea Biosciences Inc 's Total Liabilities $ 26 Millions Visit GNCA's Balance sheet
Source of GNCA's Sales Visit GNCA's Sales by Geography


Cumulative Genocea Biosciences Inc 's Leverage Ratio

GNCA's Leverage Ratio for the trailling 12 Months

GNCA Leverage Ratio

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Equity TTM Growth 602.89 % 201.44 % 87.23 % -49.55 % -86.46 %
Y / Y Total Liabilities TTM Growth -67.87 % -67.72 % -68.5 % 125.77 % 155.37 %
Leverage Ratio TTM 1.91 2.99 5.17 9.46 7.44
Total Ranking TTM # 3394 # 3428 # 127 # 3700 # 3369
Seq. Equity TTM Growth -54.26 % -28.43 % 832.9 % 130.14 % -80.38 %
Seq. Total Liabilities TTM Growth -8.61 % 6.66 % -63.06 % -10.77 % -8.19 %


On the trailing twelve months basis Due to repayements of liabilities of -8.61% Genocea Biosciences Inc decreased Leverage Ratio in the 12 months ending in I Quarter 2022 to 1.91, below the company's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 154, during the past 12 months, other companies have achieved lower Leverage Ratio than Genocea Biosciences Inc . While Leverage Ratio total ranking has improved so far to 3394, from total ranking in previous 12 month period at 3428.

Explain Leverage Ratio?
Who are GNCA Customers?
What are GNCA´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 155
Healthcare Sector # 949
Within the Market # 3394


trailing twelve months Leverage Ratio Statistics
High Average Low
9.46 2.98 0.31
(Jun 30 2021)   (Dec 31 2016)




Companies with similar Leverage Ratio in the quarter ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Leverage RatioMar 31 2022 MRQ Total LiabilitiesMar 31 2022 MRQ Equity
Elutia inc   5.62 $ 36.847  Millions$ 6.559  Millions
Inhibrx Inc   4.62 $ 126.299  Millions$ 27.350  Millions
Ladrx Corporation  4.04 $ 5.112  Millions$ 1.266  Millions
Gamida Cell Ltd   3.78 $ 94.412  Millions$ 24.984  Millions
Halozyme Therapeutics Inc   3.47 $ 901.992  Millions$ 260.256  Millions
Sorrento Therapeutics Inc   2.78 $ 629.094  Millions$ 226.198  Millions
Eloxx Pharmaceuticals Inc   2.73 $ 31.932  Millions$ 11.686  Millions
Alector Inc   2.57 $ 686.920  Millions$ 267.537  Millions
Acorda Therapeutics Inc   2.33 $ 296.589  Millions$ 127.549  Millions
Taysha Gene Therapies Inc   2.27 $ 115.251  Millions$ 50.725  Millions
Oyster Point Pharma Inc   2.16 $ 120.727  Millions$ 55.993  Millions
Genocea Biosciences Inc   2.13 $ 26.403  Millions$ 12.385  Millions
Nanostring Technologies Inc   2.06 $ 299.415  Millions$ 145.305  Millions
Champions Oncology Inc   1.96 $ 17.870  Millions$ 9.096  Millions
Valneva Se  1.83 $ 449.733  Millions$ 246.173  Millions
Gilead Sciences Inc   1.81 $ 36,016.000  Millions$ 19,915.000  Millions
Evaxion Biotech A  1.65 $ 13.722  Millions$ 8.303  Millions
Precision Biosciences Inc  1.60 $ 111.692  Millions$ 69.659  Millions
Adaptimmune Therapeutics Plc  1.57 $ 256.654  Millions$ 163.145  Millions
Humacyte Inc   1.55 $ 160.578  Millions$ 103.890  Millions
Cannabis Global Inc.  1.47 $ 11.657  Millions$ 7.931  Millions
Adma Biologics Inc   1.35 $ 171.519  Millions$ 126.933  Millions
Codiak Biosciences Inc   1.34 $ 64.783  Millions$ 48.379  Millions
Axcella Health Inc   1.18 $ 35.252  Millions$ 29.892  Millions
Biogen Inc   1.10 $ 12,372.100  Millions$ 11,220.700  Millions
Mink Therapeutics Inc   1.09 $ 18.834  Millions$ 17.308  Millions
Poseida Therapeutics Inc   1.09 $ 112.555  Millions$ 103.702  Millions
Greenlight Biosciences Holdings Pbc  1.02 $ 64.824  Millions$ 63.826  Millions
X4 Pharmaceuticals Inc  0.98 $ 48.802  Millions$ 49.714  Millions
Sangamo Therapeutics Inc   0.96 $ 319.788  Millions$ 334.522  Millions

Date modified: 2023-03-25T04:00:08+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com